Fig. 5

A combined epigenetic and immune therapy improves survival in Apc^Min/+; p16^cis/cis mice. A Study design and treatment scheme for single anti-PD-L1 mAB therapy vs. a combination of the epigenetic hypomethylating agent DAC and anti-PD-L1 mAB. B Kaplan Meier survival analysis after anti-PD-L1 or control IgG treatments in Apc^Min/+; p16^cis/cis mice. C Kaplan Meier survival analysis of Apc^Min/+; p16^cis/cis mice treated with DAC plus control IgG vs. DAC plus PD-L1. Survival curves were compared using a log-rank test